“The CADISS trial has certainly provided a great opener for future research,” added Dr. Lau, who was not involved in the study. “Specifically, what role do novel oral anticoagulants (NOACs) have in management of cervical-artery dissection? Will starting this therapy within zero to three months have any significant difference versus starting after three months? This was a relatively small study in the U.K. and Australia—how generalizable is it in your patient population?”
Dr. Lau noted that his responses solely reflect his own opinions and do not reflect those of the U.S. Government, the Department of Defense, or the Department of the Navy.
Dr. Markus did not respond to a request for comments.